RyboDyn, Inc., based in San Diego, CA, is a biotechnology company pioneering the development of first-in-class immunotherapies targeting the dark genome. By leveraging RyboCypher™, a novel RNA sequencing method with AI models trained on proprietary transcriptomic and proteomic databases, RyboDyn is uncovering and validating previously unknown proteins and disease-specific targets. With its scalable, in-house platform for lead discovery and optimization and proprietary IP licensed from Oregon Health & Science University, RyboDyn is driving a unique “targets-to-assets” approach to therapeutic development. The company collaborates with leading clinical and academic institutions as well as biopharma partners to validate and advance its drug pipeline, focusing on transformative solutions for cancer and other diseases with unmet medical needs.